Aimei Health (AFJK) Sees Shares Surge Over 1,000% Before Declining in After-Hours Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Benzinga
Stock Performance: Aimei Health Technology Co., Ltd. (AFJK) shares surged 1,006.25% on Tuesday but fell 46.89% in after-hours trading, closing at $47. The stock has seen a year-to-date increase of 724.79% and a five-day rise of 884.43%.
Merger Details: AFJK, a SPAC, is set to merge with United Hydrogen Group Inc., a Chinese hydrogen energy company, with the business combination termination date extended to January 6, 2026.
SEC Filing: A Form 8-K was filed with the SEC, revealing a deposit of $34,330.96 into the company’s trust account for public shareholders, marking the thirteenth monthly extension allowed under the company's amended articles of association.
Promissory Note Issued: The company issued an unsecured promissory note of $34,330.96 to its sponsor and United Hydrogen Group, which can be converted into private units at $10 per unit, with the note due upon the completion of the merger.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFJK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFJK
About AFJK
Aimei Health Technology Co., Ltd. is a blank check company. The Company is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company do not have any specific business combination under consideration and has not nor has anyone on behalf, directly or indirectly, contacted any prospective target business. It has not generated any revenues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aimei Health Technology Terminates Business Combination Agreement
- Termination of Agreement: Aimei Health Technology has announced the termination of its Business Combination Agreement with United Hydrogen Group, originally dated June 19, 2024, and amended on June 6, 2025, highlighting challenges in the company's M&A strategy.
- Notice Issued: The company delivered a notice of termination to United Hydrogen on July 7, 2026, under Section 9.1(b) of the agreement, indicating that the merger could not be completed within the required timeframe, which impacts the company's strategic development.
- CEO Statement: CEO Xie Junheng stated that despite the inability to finalize the merger within the stipulated time, the company remains confident in its ability to identify and execute compelling transactions in the future, reflecting a positive outlook for future growth.
- Market Reaction Anticipation: The termination of this merger agreement may negatively impact the company's stock price, prompting investors to closely monitor the company's future strategic direction and potential transaction opportunities.
See More
Aimei Health Technology Fails to File Quarterly Report on Time
- Compliance Notice: Aimei Health Technology received a notice from Nasdaq on Wednesday for failing to comply with listing rules due to a delay in filing its quarterly report for the period ended March 31, which was due on May 15, indicating potential issues in the company's financial transparency.
- Listing Impact: Despite the notice, Aimei stated that it has no immediate effect on its listing or trading of securities on Nasdaq, suggesting that the company can maintain its market position in the short term.
- Compliance Plan Timeline: Under Nasdaq rules, the company has 60 calendar days to file the report or submit a compliance plan, providing a buffer period to address compliance issues and avoid more severe consequences.
- Potential Consequences: If the compliance plan is accepted, Nasdaq may grant the company up to 180 days to regain compliance, offering flexibility for the company to improve its financial reporting processes and maintain investor confidence.
See More
WhiteFiber Inc (WYFI) Announces $200 Million Convertible Notes Offering, Shares Drop 5.5%
- Convertible Notes Offering: WhiteFiber Inc announced a $200 million convertible notes offering, resulting in a 5.5% drop in its share price during pre-market trading, which may negatively impact investor confidence and future financing capabilities.
- Market Reaction: Following the convertible notes announcement, WhiteFiber's stock fell to $19.19 in pre-market trading, reflecting market concerns over the company's financial health and potentially affecting shareholder returns.
- Other Stock Movements: Caleres, Inc. shares tumbled 8.6% in pre-market trading after naming Dan Karpel as interim CFO, indicating that changes in corporate governance may impact its market performance.
- Overall Industry Trends: Aura Biosciences Inc shares dipped 7%, while GoldMining Inc and T1 Energy Inc fell 5.5% and 5.4% respectively, suggesting a general downturn in market sentiment that could affect investor confidence across related sectors.
See More
mF International Files Mixed Shelf, Shares Drop 4.6%
- Stock Decline: mF International's shares fell 4.6% to $17.61 in pre-market trading, reflecting market concerns over its mixed shelf filing, which may impact investor confidence and liquidity.
- Market Reaction: SBC Medical Group's stock plummeted 18.9% to $3.51 in pre-market trading, indicating negative sentiment in the healthcare sector that could affect the company's future financing capabilities.
- Other Stock Movements: Aimei Health Technology's shares declined 7.7% to $70.00, suggesting cautious market sentiment regarding its outlook, which may impact its market share and investor appeal.
- Executive Change: NetEase announced the retirement of Yingfeng Ding, EVP of the Interactive Entertainment Group, which could lead to strategic shifts affecting the future performance of its online gaming division.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
Ironwood Pharmaceuticals Issues FY26 Guidance, Shares Surge 57.7%
- Sales Guidance Boost: Ironwood Pharmaceuticals anticipates 2026 US net sales for Linzess to reach between $1.125 billion and $1.175 billion, indicating strong market demand that is expected to drive future revenue growth.
- Revenue Expectations Rise: The company projects total revenue for 2026 to be between $450 million and $475 million, which is likely to enhance investor confidence and attract more capital inflow.
- Strong EBITDA Forecast: Ironwood expects adjusted EBITDA to exceed $300 million in 2026, indicating ongoing improvements in profitability that could elevate its market valuation.
- Significant Stock Surge: Following the announcement, Ironwood's shares surged 57.7% to $5.32, reflecting a positive market reaction to its growth potential.
See More
Aimei Health Technology Terminates Business Combination Agreement
- Termination of Agreement: Aimei Health Technology has announced the termination of its Business Combination Agreement with United Hydrogen Group, originally dated June 19, 2024, and amended on June 6, 2025, highlighting challenges in the company's M&A strategy.
- Notice Issued: The company delivered a notice of termination to United Hydrogen on July 7, 2026, under Section 9.1(b) of the agreement, indicating that the merger could not be completed within the required timeframe, which impacts the company's strategic development.
- CEO Statement: CEO Xie Junheng stated that despite the inability to finalize the merger within the stipulated time, the company remains confident in its ability to identify and execute compelling transactions in the future, reflecting a positive outlook for future growth.
- Market Reaction Anticipation: The termination of this merger agreement may negatively impact the company's stock price, prompting investors to closely monitor the company's future strategic direction and potential transaction opportunities.
See More
Aimei Health Technology Fails to File Quarterly Report on Time
- Compliance Notice: Aimei Health Technology received a notice from Nasdaq on Wednesday for failing to comply with listing rules due to a delay in filing its quarterly report for the period ended March 31, which was due on May 15, indicating potential issues in the company's financial transparency.
- Listing Impact: Despite the notice, Aimei stated that it has no immediate effect on its listing or trading of securities on Nasdaq, suggesting that the company can maintain its market position in the short term.
- Compliance Plan Timeline: Under Nasdaq rules, the company has 60 calendar days to file the report or submit a compliance plan, providing a buffer period to address compliance issues and avoid more severe consequences.
- Potential Consequences: If the compliance plan is accepted, Nasdaq may grant the company up to 180 days to regain compliance, offering flexibility for the company to improve its financial reporting processes and maintain investor confidence.
See More
WhiteFiber Inc (WYFI) Announces $200 Million Convertible Notes Offering, Shares Drop 5.5%
- Convertible Notes Offering: WhiteFiber Inc announced a $200 million convertible notes offering, resulting in a 5.5% drop in its share price during pre-market trading, which may negatively impact investor confidence and future financing capabilities.
- Market Reaction: Following the convertible notes announcement, WhiteFiber's stock fell to $19.19 in pre-market trading, reflecting market concerns over the company's financial health and potentially affecting shareholder returns.
- Other Stock Movements: Caleres, Inc. shares tumbled 8.6% in pre-market trading after naming Dan Karpel as interim CFO, indicating that changes in corporate governance may impact its market performance.
- Overall Industry Trends: Aura Biosciences Inc shares dipped 7%, while GoldMining Inc and T1 Energy Inc fell 5.5% and 5.4% respectively, suggesting a general downturn in market sentiment that could affect investor confidence across related sectors.
See More
mF International Files Mixed Shelf, Shares Drop 4.6%
- Stock Decline: mF International's shares fell 4.6% to $17.61 in pre-market trading, reflecting market concerns over its mixed shelf filing, which may impact investor confidence and liquidity.
- Market Reaction: SBC Medical Group's stock plummeted 18.9% to $3.51 in pre-market trading, indicating negative sentiment in the healthcare sector that could affect the company's future financing capabilities.
- Other Stock Movements: Aimei Health Technology's shares declined 7.7% to $70.00, suggesting cautious market sentiment regarding its outlook, which may impact its market share and investor appeal.
- Executive Change: NetEase announced the retirement of Yingfeng Ding, EVP of the Interactive Entertainment Group, which could lead to strategic shifts affecting the future performance of its online gaming division.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
Ironwood Pharmaceuticals Issues FY26 Guidance, Shares Surge 57.7%
- Sales Guidance Boost: Ironwood Pharmaceuticals anticipates 2026 US net sales for Linzess to reach between $1.125 billion and $1.175 billion, indicating strong market demand that is expected to drive future revenue growth.
- Revenue Expectations Rise: The company projects total revenue for 2026 to be between $450 million and $475 million, which is likely to enhance investor confidence and attract more capital inflow.
- Strong EBITDA Forecast: Ironwood expects adjusted EBITDA to exceed $300 million in 2026, indicating ongoing improvements in profitability that could elevate its market valuation.
- Significant Stock Surge: Following the announcement, Ironwood's shares surged 57.7% to $5.32, reflecting a positive market reaction to its growth potential.
See More
